Lotus Pharmaceutical Co., Ltd. (TPE:1795)

Lotus Pharmaceutical Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 25, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	67,060	71,524	71,935	64,462	25,569	19,628
Market Cap Growth	-11.69%	-0.57%	11.59%	152.11%	30.27%	-29.79%
Enterprise Value	74,564	80,276	81,666	71,660	30,851	25,397
Last Close Price	255.00	262.47	260.17	232.56	90.84	74.29
PE Ratio	13.80	14.12	17.52	21.34	18.22	19.12
Forward PE	11.20	12.05	15.36	18.39	15.41	16.33
PS Ratio	3.51	3.85	4.24	4.41	2.02	1.83
PB Ratio	3.29	3.38	4.15	4.65	2.31	2.24
P/TBV Ratio	8.25	7.26	11.65	28.14	10.18	-
P/FCF Ratio	9.96	12.33	59.77	20.52	-	12.79
P/OCF Ratio	9.42	11.62	44.56	17.33	213.68	10.07
EV/Sales Ratio	3.90	4.32	4.82	4.90	2.44	2.37
EV/EBITDA Ratio	9.47	10.95	13.23	14.07	9.63	10.74
EV/EBIT Ratio	11.45	12.99	16.07	16.86	12.20	14.59
EV/FCF Ratio	11.07	13.84	67.85	22.81	-	16.55
Debt / Equity Ratio	0.57	0.65	0.67	0.64	0.63	0.78
Debt / EBITDA Ratio	1.48	1.83	1.84	1.72	2.12	2.80
Debt / FCF Ratio	1.73	2.36	9.63	2.84	-	4.45
Asset Turnover	0.53	0.51	0.54	0.58	0.62	0.56
Inventory Turnover	1.99	2.01	2.13	2.13	2.65	3.45
Quick Ratio	1.10	1.63	1.85	1.17	1.16	0.88
Current Ratio	1.55	2.15	2.80	1.81	1.93	1.39
Return on Equity (ROE)	25.03%	26.30%	26.32%	24.23%	14.16%	12.48%
Return on Assets (ROA)	11.18%	10.57%	10.16%	10.47%	7.71%	5.73%
Return on Capital (ROIC)	13.31%	12.12%	12.29%	13.02%	9.41%	7.10%
Return on Capital Employed (ROCE)	22.90%	19.50%	17.90%	18.00%	15.00%	11.70%
Earnings Yield	7.25%	7.08%	5.71%	4.69%	5.49%	5.23%
FCF Yield	10.04%	8.11%	1.67%	4.88%	-1.77%	7.82%
Dividend Yield	2.25%	2.18%	1.79%	1.49%	2.13%	0.47%
Payout Ratio	25.34%	24.32%	22.07%	16.75%	6.56%	-
Buyback Yield / Dilution	-0.06%	-0.53%	-0.13%	-1.95%	-5.43%	-0.65%
Total Shareholder Return	2.19%	1.66%	1.66%	-0.46%	-3.30%	-0.18%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.